Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

1.15
+0.04003.60%
Post-market: 1.160.0100+0.87%19:34 EST
Volume:1.41M
Turnover:1.59M
Market Cap:132.66M
PE:-0.87
High:1.17
Open:1.12
Low:1.09
Close:1.11
52wk High:2.07
52wk Low:0.6611
Shares:115.35M
Float Shares:100.80M
Volume Ratio:1.32
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3180
EPS(LYR):-1.6384
ROE:-52.35%
ROA:-23.85%
PB:0.57
PE(LYR):-0.70

Loading ...

Fate Therapeutics Reports Promising Phase 1 Results for Off-the-Shelf CAR T-Cell Therapy in Lupus

Reuters
·
Dec 08

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire
·
Nov 25

Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts

TIPRANKS
·
Nov 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Nov 17

Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks

TIPRANKS
·
Nov 16

Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities

TIPRANKS
·
Nov 16

Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)

TIPRANKS
·
Nov 14

Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment

TIPRANKS
·
Nov 13

Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate

Benzinga
·
Nov 13

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

TIPRANKS
·
Nov 13

Fate Therapeutics reports third quarter 2025 revenue of $1.7 million

Reuters
·
Nov 13

Fate Therapeutics Q3 Net Income USD -32.25 Million

THOMSON REUTERS
·
Nov 13

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

GlobeNewswire
·
Nov 13

Fate Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Nov 07

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 05

Fate Therapeutics Shares Rise After HC Wainwright Upgrade

MT Newswires Live
·
Nov 01

HC Wainwright Upgrades Fate Therapeutics to Buy From Neutral, $5 Price Target

MT Newswires Live
·
Oct 31

Fate Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
Oct 31

Fate Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
Oct 31

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

TIPRANKS
·
Oct 27